NRD
ANAB icon

Nebula Research & Development’s AnaptysBio ANAB Stock Holding History

Nebula Research & Development’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,533
Closed -$345K – 55
2025
Q2 		$345K Buy
15,533
+28
+0.2% +$586 0.03% 750
2025
Q1 		$288K Sell
15,505
-1,917
-11% -$32K 0.03% 766
2024
Q4 		$231K Buy
+17,422
New +$422K 0.03% 775

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nebula Research & Development's ANAB Position: Q3 2025 in Review

Nebula Research & Development sold out of AnaptysBio (ANAB) in Q3 2025, closing a stake of 15,533 shares — an estimated $345K sold.

Nebula Research & Development first reported a position in ANAB in Q4 2024 and held it in 3 quarters. The position peaked at $345K in Q2 2025. 166 funds tracked by Wall St. Rank hold ANAB as of Q3 2025.

  • Nebula Research & Development reported no remaining AnaptysBio position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 15,533 AnaptysBio shares in Q3 2025, an estimated $345K.
  • Nebula Research & Development first reported a position in AnaptysBio in Q4 2024 and held it in 3 quarters.
  • Nebula Research & Development's AnaptysBio position peaked at $345K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.